325 related articles for article (PubMed ID: 19857854)
1. Treatment options for hyperphosphatemia in feline CKD: what's out there?
Kidder AC; Chew D
J Feline Med Surg; 2009 Nov; 11(11):913-24. PubMed ID: 19857854
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
4. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
5. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
6. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
7. Feline chronic renal failure: long-term medical management.
Plotnick A
Compend Contin Educ Vet; 2007 Jun; 29(6):342-4, 346-50; quiz 351. PubMed ID: 17724988
[TBL] [Abstract][Full Text] [Related]
8. Serum fibroblast growth factor 23 (FGF-23): associations with hyperphosphatemia and clinical staging of feline chronic kidney disease.
Lin J; Lin L; Chen S; Yu L; Chen S; Xia Z
J Vet Diagn Invest; 2021 Mar; 33(2):288-293. PubMed ID: 33543676
[TBL] [Abstract][Full Text] [Related]
9. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
10. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
11. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
12. The role of phosphorus in the pathophysiology of chronic kidney disease.
Geddes RF; Finch NC; Syme HM; Elliott J
J Vet Emerg Crit Care (San Antonio); 2013; 23(2):122-33. PubMed ID: 23464730
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of daily and intermittent-dose calcitriol on serum parathyroid hormone and ionized calcium concentrations in normal cats and cats with chronic renal failure.
Hostutler RA; DiBartola SP; Chew DJ; Nagode LA; Schenck PA; Rajala-Schultz PJ; Drost WT
J Vet Intern Med; 2006; 20(6):1307-13. PubMed ID: 17186842
[TBL] [Abstract][Full Text] [Related]
14. Feline CKD: Pathophysiology and risk factors--what do we know?
Reynolds BS; Lefebvre HP
J Feline Med Surg; 2013 Sep; 15 Suppl 1():3-14. PubMed ID: 23999182
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the transforming growth factor-beta 1 signalling pathway as a possible link between hyperphosphataemia and renal fibrosis in feline chronic kidney disease.
Lawson JS; Syme HM; Wheeler-Jones CPD; Elliott J
Vet J; 2021 Jan; 267():105582. PubMed ID: 33375963
[TBL] [Abstract][Full Text] [Related]
16. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
17. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent of suppress toxic hyperparathyroidism.
Nagode LA; Chew DJ; Podell M
Vet Clin North Am Small Anim Pract; 1996 Nov; 26(6):1293-330. PubMed ID: 8911021
[TBL] [Abstract][Full Text] [Related]
18. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
Sigrist MK; Chiarelli G; Lim L; Levin A
J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
[TBL] [Abstract][Full Text] [Related]
19. Feline CKD: Current therapies - what is achievable?
Korman RM; White JD
J Feline Med Surg; 2013 Sep; 15 Suppl 1():29-44. PubMed ID: 23999184
[TBL] [Abstract][Full Text] [Related]
20. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
